APOP - Cellect Biotechnology Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.0500
+0.1400 (+2.85%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close4.9100
Open5.0500
Bid4.8500 x 3000
Ask7.1000 x 800
Day's Range4.9199 - 5.2300
52 Week Range4.4000 - 13.5000
Volume7,658
Avg. Volume17,446
Market Cap32.874M
Beta (3Y Monthly)3.66
PE Ratio (TTM)N/A
EPS (TTM)-0.9310
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Cellect Announces Positive Clinical Results

    TEL AVIV, Israel, Oct. 15, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today further data from a Phase I/II study of its ApoGraft™ technology. With half of the patients planned for the study having finished first month follow up, all such patients have shown 100% engraftment with no procedure related adverse events reported. Further to the six patients' one month data detailed above, Cellect reports that the first three patients of the trial (cohort I) have completed the study period (180 days) with full safety and tolerability.

  • PR Newswire2 months ago

    Cellect Receives Notice of Allowance for Stem Cell Selection Technology Patent in Korea

    TEL AVIV, Israel, Aug. 20, 2018 /PRNewswire/ --  Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today it has received a Notice of Allowance from the Korean Intellectual Property Office for its patent titled, "Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof". This patent, recently granted to Cellect in Europe, addresses the Company's ApoTainer™ device which is used in conjunction with its platform ApoGraft™ technology.

  • PR Newswire2 months ago

    Cellect and Cell2in Launch Collaboration to Significantly Improve Stem Cell Selection and Expansion

    TEL AVIV, Israel, Aug. 13, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today that it has signed a collaboration agreement with Cell2in, a South Korean company focused on improving the quality of cells. Cell2in's FreSHtracer™ technology and its unique characteristics may improve the functionality and efficacy of Cellect's ApoGraft™ technology through the selection of desirable stem cells and quantification of the expansion process. Better quantification of quality stem cells is expected to lead to continuous improvements in Cellect's technology platform.

  • PR Newswire2 months ago

    Cellect Biotechnology Provides Corporate Update and Reports Second Quarter 2018 Financial Results

    TEL AVIV, Israel , Aug. 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire2 months ago

    Cellect Granted Key European Patent for Its Stem Cell Selection Technology

    TEL AVIV, Israel, Aug. 7, 2018  /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today the European Patent Office has granted the company a patent for its platform ApoGraft™ technology and ApoTainer™ device titled, "Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof". Through negative selection, Cellect's technology identifies mature cells that can be harmful to the recipient and selectively eliminates those cells through apoptosis (cell death).

  • PR Newswire3 months ago

    Cellect Signed Strategic Agreement with Swiss Biotech Center (SBC)

    TEL AVIV, Israel, July 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced that it has entered into a strategic manufacturing and supply agreement with Swiss Biotech Center (SBC) to secure production of FasL protein - Cellect's main active ingredient in ApoGraft™ and the line of Apotainer™.

  • PR Newswire3 months ago

    Cellect Signs Collaboration Agreement With Dresden University denovoMATRIX Team

    Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced that it has signed a collaboration and material transfer agreement with the denovoMATRIX group of the Technische Universität Dresden (TU Dresden). TU Dresden and its Center for Regenerative Therapies Dresden (CRTD), is one of the leading centers for stem cell research in Germany.

  • PR Newswire5 months ago

    Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2018 Financial Results

    TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire5 months ago

    Former GE Healthcare Executive to Join Cellect as Chief Business Officer

    Andrew Sabatier, formerly the US Sales and Market Development Leader for GE Cell Therapy, will be heading up the commercialization of Cellect Apograft™ technology, as well as new business development. Dr. Shai Yarkoni, Cellect CEO commented: "We are now focusing on building the strongest team possible for the commercialization of our technology. Andrew is one of the most experienced and respected sales executives in this industry with a proven track record of successfully commercializing cell therapy products.

  • PR Newswire6 months ago

    Cellect Announces a Major Milestone for Enabling Stem Cells Production

    Dr. Shai Yarkoni, Cellect CEO commented: "We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. TEL AVIV, Israel, April 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell enabling technology, announced that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer™ using Cellect's FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell based products' manufacturing.

  • PR Newswire7 months ago

    Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

    TEL AVIV, Israel , March 19, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a ...

  • PR Newswire8 months ago

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

    On January 29, 2018, Cellect announced that it had entered into a securities purchase agreement with certain institutional investors for gross proceeds of approximately $4 million. The company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered warrant to purchase 55% of an ADS.

  • PR Newswire8 months ago

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

    On January 29, 2018, Cellect announced that it had entered into a securities purchase agreement with certain institutional investors for gross proceeds of approximately $4 million. The company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered warrant to purchase 55% of an ADS.

  • CNW Group8 months ago

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

    Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

  • PR Newswire9 months ago

    Cellect Biotechnology Announces $4 Million Registered Direct Offering

    Cellect Biotechnology Ltd. (APOP), a developer of stem cells selection technology, announced that it has entered into securities purchase agreements with certain institutional investors for gross proceeds of approximately $4 million. In connection with the offering, the Company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering.  Additionally, for each ADS purchased, the investors will receive an unregistered warrant to purchase 55% of an ADS. The warrants have an exercise price of $12.00 per ADS, shall be exercisable immediately following the issuance date and will expire twelve months from the earlier of the effectiveness date of a registration statement registering the shares underlying the warrants and 6 months from the issuance date of the warrants.

  • PR Newswire9 months ago

    Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation

    TEL AVIV, Israel, Jan. 16, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell selection technology, announced that it has signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect's ongoing Phase I/II study. The study at Hadassah will be conducted under Prof. Polina Stefenski, the Principal Investigator of the site at Hadassah.

  • PR Newswire9 months ago

    Cellect Announces Breakthrough Clinical Results

    First Group of Patients in Clinical Trial With Cellect's ApoGraft Stem Cell Transplant Follow up Results 100% Acceptance and Zero Related Adverse Events Dr. Shai Yarkoni, Cellect CEO commented: "These ...

  • PR Newswire11 months ago

    Cellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2017 Financial Results

    TEL AVIV, Israel , Nov. 22, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire11 months ago

    Cellect CEO, Dr. Shai Yarkoni Selected as Keynote Speaker at the 11th World Congress of Regenerative Medicine & Stem Cell in Singapore

    Cellect Biotechnology Ltd. (APOP), a developer of stem cells selection technology, announced today that Company CEO, Dr. Shai Yarkoni, was selected to provide the keynote (Plenary) presentation at the 11th world congress of Regenerative Medicine and Stem Cell technologies (http://www.bitcongress.com/rmsc2017/default.asp ). The event is intended to provide a platform for professionals around the world to exchange state-of-the-art research and development and identify business trends, needs and opportunities in the field of Regenerative Medicine & Stem Cell.

  • PR Newswirelast year

    Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading Companies

    TEL AVIV, Israel, Oct. 31, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP),a developer of stem cell selection technology, announced today that Company CEO, Dr. Shai Yarkoni, was chosen to present Cellect technology and recent advancements at the Bio-Europe 2017 conference in Berlin (https://ebdgroup.knect365.com/bioeurope/about-bio-europe) alongside other selected industry leaders including Andrew Yost, VP, Corporate Development, REGENXBIO Inc., Gabriele Proetzel, Director, Regenerative Medicine, Takeda and Sharon Brownlow, Head of Collaborations - Manufacturing Centre, The Cell and Gene Therapy Catapult. The panel will be moderated by the Founder of Alliance of Regenerative Medicine (ARM).

  • SmarterAnalystlast year

    Cellect Biotechnology Ltd. (APOP) Celebrates Major Milestone

    Cellect Biotechnology Ltd. (NASDAQ:APOP) investors are busy throwing a party today following the news that the stem cell developer has achieved a major milestone with the conclusion of a large study on the use ApoGraft™ on stem cells derived from fat tissues. The significance of the findings opens ApoGraft™ to be used by a much wider array of companies and medical centers worldwide developing stem cell based products and treatments. Of special importance are the aesthetic and orthopedic indications where fat-derived stem cells are the main raw material.

  • PR Newswirelast year

    Cellect Announces a Major Breakthrough of its ApoGraft™ Technology: Reporting Today Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical Center

    Dr. Shai Yarkoni: "This breakthrough finding is increasing our addressable market by an order of magnitude. TEL AVIV, Israel, Oct 25, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of stem cell selection technology, announced today that it has achieved a major milestone with the conclusion of a large study on the use ApoGraft™ on stem cells derived from fat tissues. The significance of the findings opens ApoGraft™ to be used by a much wider array of companies and medical centers worldwide developing stem cell based products and treatments.

  • PR Newswirelast year

    Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer

    Dr. Bakimer-Kleiner has over twenty years of experience as a scientist and executive manager in the biotechnological industrial environment. Ronit has been involved in project planning and management, product development from the bench to production.